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Breast cancer is the most frequent malignancy of the female popu-
lation in the Western world. Prognosis of disease and treatment
strategies are mainly determined by the presence of hormone
receptors in tumour tissues. At the time of diagnosis about 60% of
breast carcinomas express either the oestrogen receptor (OR) or
both the oestrogen and the progesterone receptor (PR). Upon signs
of dissemination, these malignancies are treated with an
endocrinological therapy. For this purpose, mainly the anti-
oestrogen tamoxifen (TAM) is primarily used. Unfortunately,
about 1/3 of hormone receptor-positive breast cancers initially fail
to respond to a tamoxifen therapy, and a large number of originally
sensitive tumours develop resistance during several months of
treatment (Early Breast Cancer Trial Group 1992). Different
hypotheses have been discussed to explain the development of
TAM-resistance:
– Degradation of TAM leading to metabolites with different
anti-oestrogenic potential (Murphy et al, 1990).
– Loss or mutations of the oestrogen receptor, or of the
oestrogen responsive element (ORE) of DNA (Mahfoudi et al,
1995; Murphy et al, 1996).
– Post-translational modifications of the OR (Denton et al,
1992).
– Involvement of different co-factors in transcriptional
machinery (Landel et al, 1994; Lavinsky et al, 1998).
– Conformational changes of the secondary structure of the
OR protein (Brzozowski et al, 1997; Maalouf et al, 1998).
– Interaction of (anti-) hormones with different OR-subtypes,
OR a and b, leading to different transcription properties
(Paech et al, 1997; Barkhem et al, 1998).
– Expression of specific breast cancer anti-oestrogen resis-
tance genes (BCAR) (van Agthoven et al, 1998).
Mechanisms of anti-oestrogen resistance are mainly studied in
established cell lines whose resistance was developed by in vitro
treatment with increasing drug doses and selection of clones
being able to grow in culture in the presence of anti-oestrogens
(overview Lykkesfeldt, 1996; Katzenellenbogen et al, 1997).
Culture conditions cannot completely mimic the in vivo environ-
ment and dynamic regulation mechanisms working in intact indi-
viduals, but probably select certain specific mechanisms of cell
proliferation and resistance. We decided to develop a TAM-
resistant subline of an originally very sensitive breast carcinoma
xenograft (3366) by in vivo treatment of tumour-bearing nude
mice with increasing doses of the anti-oestrogen. This procedure
was performed during passaging of the xenograft over a period of
3 years. The established TAM-resistant subline (3366/TAM) was
characterized according to histology and growth, cytostatic and
anti-oestrogen resistance, expression of hormone receptors and
hormone receptor dependent genes.
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Summary A human tamoxifen-resistant mammary carcinoma, MaCa 3366/TAM, originating from a sensitive parental xenograft 3366 was
successfully established by treatment of tumour-bearing nude mice with 1–50 mg kg–1 tamoxifen for 3 years during routine passaging. Both
tumours did not differ significantly in OR- and PR-positivity, however, when compared with the sensitive tumour line, the mean OR content of
the TAM-resistant subline is slightly lower. An OR-upregulation following withdrawal of oestradiol treatment was observed in the parental
tumours but not in the resistant xenografts. Following long-term treatment with tamoxifen, the histological pattern of the breast carcinoma
changed. The more differentiated structures being apparent after treatment with 17b-oestradiol in the original 3366 tumour were not induced
in the resistant line. Tamoxifen failed to induce a tumour growth inhibition in comparison to the tamoxifen-sensitive line. The pure anti-
oestrogen, ICI 182 780, revealed cross-resistance. Sequence analysis of the hormone-binding domain of the OR of both lines showed no
differences, suggesting that either mutations in other regions of the OR are involved in the TAM-resistance phenotype or that mechanisms
outside of this protein induced this phenotype. Oestrogen and anti-oestrogen regulate pS2 and cathepsin D expression in 3366 tumours as in
the human breast cancer cell line MCF-7. The resistant 3366/TAM tumours have lost this regulation. The established breast cancer
xenografts 3366 and 3366/TAM offer the possibility of investigating mechanisms of anti-oestrogen resistance in an in vivo situation. They can
be used to test novel approaches to prevent, or to overcome, this resistance in a clinically related manner. © 2000 Cancer Research
Campaign
Keywords: tamoxifen resistance; breast cancer; xenograft; oestrogen receptor; cathepsin D gene; pS2 gene
1844
Received 9 September 1999
Revised 13 January 2000
Accepted 18 January 2000
Correspondence to: I Fichtner
British Journal of Cancer (2000) 82(11), 1844–1850
© 2000 Cancer Research Campaign
DOI: 10.1054/ bjoc.2000.1156, available online at http://www.idealibrary.com on MATERIALS AND METHODS
Animals
Six to eight female nude mice (Bom: NMRI-nu/nu) /group, aged
4–6 weeks and weighing 20–24 g, were used for the experiments.
The conditions of breeding and maintenance of the animals have
already been described (Naundorf and Arnold, 1981). All animal
experiments were performed according to the UKCCR Guidelines
for the Welfare of Animals in Experimental Neoplasia and with
permittance of the local responsible authorities (G V247/98).
Tumour transplantation
The subcutaneous (s.c.) transplantation of the tumour pieces (size
4 ´ 4 mm) was carried out into a prepared pocket of the left flank
region of nude mice anaesthetized with Radenarkon (40 mg kg–1
i.p. Etomidat, Asta Medica, Frankfurt, Germany). The tumour
diameters were measured once weekly using a caliper-like
mechanical instrument and tumour volume (V) was calculated
according to the formula V = (length ´ width2) 2–1. The median
volumes of each group were related to the initial value (relative
tumour volume, RTV). In all experiments, if not otherwise
mentioned, tumour-bearing mice received an oestradiol supple-
mentation (oestradiol valeriate, 0.5 mg kg–1 once a week i.m.).
This supplementation leads to a physiological level of serum
oestradiol (25–984 pg ml–1) comparable with the human situation
(25–600 pg ml–1 in dependence on follicular phase).
Development of TAM-resistant mammary carcinoma
3366/TAM
The newly established TAM-resistant mammary carcinoma origi-
nated from the sensitive parental breast tumour 3366 described by
Naundorf et al (1992). The breast carcinoma-bearing nude mice
were treated with increasing doses of TAM (1–50 mg kg–1) over a
period of 3 years until loss of TAM sensitivity in vivo. Then
tumour-bearing nude mice were treated regularly once a week with
50 mg kg–1 TAM during passages, except the last passage before
an experiment.
Substances
The following substances were used: 17b-oestradiol valeriate,
E2D (Jenapharm, Jena, Germany), Tamoxifen (Sigma, Chemie
GmbH, Germany), ICI 182 780 (gift of Zeneca Pharmaceutical,
Macclesfield, UK).
Histological investigations
The histological procedures were carried out using routine
methods. For the histological preparation 5% formalin was used as
fixative and the sections of the tumour preparations were stained
with haematoxylin/eosin.
Receptor determination
The oestrogen (OR) and progesterone receptors (PR) in tumour
tissue were determined according to the Abbott OR and PR enzyme
immunoassay instructions (Abbott ER-EIA Monoclonal, Abbott
GmbH Wiesbaden, Germany). The cut-off value for a positive
receptor status for OR and PR is >15 fmol mg–1 cytosol protein.
The protein content of the cytosol fraction was determined
according to the method of Lowry et al 1951.
Nucleotide sequence determination of the hormone
binding domain
The examined breast tumour specimens were shock-frozen in
liquid nitrogen and stored at –80°C. Total RNA was isolated by the
method of guanidinium thiocyanate extraction using a reagent
system supplied by Promega (RNAgents, Promega Corporation,
Madison, USA). The isolated RNA was resuspended in 1 ´ TE-
buffer (10 mM Tris HCl pH 8.0, 1 mM EDTA), quantified spec-
trophotometrically and stored in aliquots at –80°C until used. RT
and PCR reactions were carried out using thermostable rtTh-
polymerase and appropriate rtTh PCR reagents (GeneAmp rtTh-
RNA-PCR-System, Perkin Elmer Corporation, Foster City, USA)
according to the general protocol supplied by the manufacturer.
200 ng of total RNA were reverse-transcribed in a final volume of
20 ml containing 200 mM dNTP’s, 1 mM MnCl2, 5 units rtTh-poly-
merase and 800 nM of the specific 3¢-primer (3 min at 90°C
followed by 15 min at 65°C). The subsequent cDNA amplification
was performed in a final volume of 100 ml containing the whole
RT reaction mixture, chelating buffer, 1 mM MgCl2 and 160 nM of
5¢-primer. The thermal profile of the amplification reaction
involved an initial 2 min denaturation step at 95°C followed by 35
cycles of denaturation at 94°C (1 min) and annealing/extension at
64°C (1 min) and a final elongation at 72°C for 10 min. The
selected pair of primers used in RT-PCR encompassed a 634 bp
fragment in the hormon binding region of OR mRNA: hERb5¢:
GGC TTA CTG ACC AAC CTG GCA G (pos. 1390–1411);
hERb3¢: ACG GCT AGT GGG CGC ATG TAG G (pos.
2004–2025) (positions refer to GenBank No. X03635). After
cleaning up the PCR-amplified fragment by agarose gel
electrophoresis and extraction with QiaQuick Kit (Qiagen Inc.,
Chatsworth, USA) the sequence determination was carried out by
InViTek Gmbh (Berlin-Buch) using a cycle sequencing protocol
and an ABI-PRISM automated sequence analyser (Applied
Biosystemes Inc., Foster City, USA). Both strands were
sequenced.
Expression of oestrogen receptor regulated genes
The oestrogen-regulated genes pS2 and cathepsin D were deter-
mined by Northern analysis. Frozen tissues were homogenized
in a microdismembrator with pre-cooled (–180°C) chambers.
TRIzol®Reagent (Life Technologies), 1 ml per 100 mg tissue, was
added, and total RNA isolated as recommended by the supplier.
Poly (A)+RNA was isolated with the Oligo (dT)25 coupled
magnetic beads (Dynal, Oslo, Norway) according to the manufac-
turer’s manual. Two micrograms of poly(A)+RNA were denatured
with glyoxal/DMSO solution, run on a 1.2% agarose gel and trans-
ferred to a nylon membrane (Nytran 13N, Schleicher & Schuell,
Dassel, Germany). The probe used for Northern hybridization to
pS2 was EcoRI lineriazed pS2 (Masiakowski et al, 1982), the
probe for cathepsin D was oligonucleotide 5¢-TTAACGTAGGT-
GCTGGACTTGTCGCTGTTGTACTT-3¢ (Augereau et al, 1988).
The 1.1 kb PstI fragment of 36B4 from MCF-7 cloned into the
pBR322 vector (Laborda, 1991) was used as a control for loading.
The plasmid-derived probes were labelled with [a-32P]-dCTP
(Amersham, Aylesbury, UK) using the Megaprime DNA labelling
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and Northern blots were hybridized as described (Madsen et al,
1992). The oligonucleotide probe was end-labelled with [g-32P]-
ATP (Amersham) to a specific activity of 0.5–2 ´ 107 dpm pmol–1
using T4 polynucleotide kinase (BRL). Northern blots were
hybridized as described (Lykkesfeldt et al, 1994). The blots were
exposed to Kodak X-OMAT AR-5 films at –80°C. For quanti-
fication, the blots were exposed to a PhosphorImager screen
(Molecular Dynamics, Sunnyvale, CA, USA) for 1–5 days and the
ImageQuant software was used for the calculations.
RESULTS
Histological characterization of the human mammary
carcinomas 3366 and 3366/TAM
Histological studies of the sensitive breast carcinoma 3366
revealed a solid ductal invasive mammary carcinoma with
moderate differentiation (Figure 1A). After treatment of tumour
bearing nude mice with 0.5 mg kg–1 17b-oestradiol for 4 weeks,
histological pattern of tumour changed to an 80% duct-forming
growth (Figure 1B), whereas in the untreated tumour the solid
growth prevailed. When the tamoxifen-resistant subline was
treated with oestrogen, the histological appearance did not change,
in comparison to the untreated control (Figures 1C and 1D).
Growth behaviour of mammary carcinomas 3366 and
3366/TAM
As Figure 2 shows, the growth of the breast carcinoma 3366 in
nude mice was strongly dependent on the supplementation with
oestrogen. While the saline-treated tumours remained small in size
(4–5 mm diameter), a treatment of mice with 0.5 mg kg–1 oestra-
diol valeriate once a week during the experimental period of 10
weeks led to an approximately 20-fold increase of tumour volume.
The anti-oestrogens TAM and ICI 182 780 completely prevented
the growth of the xenografts, even when combined with oestradiol.
Similar therapeutic effects in the 3366 xenografts were also
obtained, when the tumours were transplanted to oestradiol
supplemented male or ovariectomized female nude mice, and
TAM was also active following oral or intraperitoneal routes of
administration (data not shown). The TAM-resistant subline
3366/TAM (Figure 3) is similarly stimulated in growth by oestra-
diol. The anti-oestrogens TAM and ICI 182 780 administered to
oestrogen supplemented mice are not able to significantly prevent
it. In the experiment presented, TAM and ICI treatment of mice
without oestradiol supplementation led to a growth similar to the
solvent-treated tumours, while in three of seven experiments TAM
stimulated growth (data not shown), indicating its partial oestro-
genic properties. The TAM-resistance was persistent for up to six
tumour passages without TAM treatment of nude mice.
Hormone receptor expression
Both the original xenograft 3366 and the TAM-resistant subline
express OR (113 ± 64 or 194 ± 55 fmol mg–1 protein, respectively,
obtained as mean ± standard deviation from 5–8 tumours each)
and can therefore be considered as being OR positive. When
tumour-bearing mice were treated for 6 weeks with 17b-oestradiol
valeriate (E2D) and the xenografts were harvested at several days
after last treatment, a regulation of OR expression became evident
(Figure 4). In the breast carcinoma 3366 a short period of
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Figure 1 Histology of breast cancer xenografts. (A) 3366, untreated; (B) 3366 treated for 4 weeks with 17b-oestradiol valeriate (0.5 mg kg–1 once a week i.m.);
(C) 3366/TAM untreated; (D) 3366/TAM, treated for 4 weeks with 17b-oestradiol valeriate. Magnification ´ 150decreased levels (day 1) is followed by a significant upregulation,
lasting for more than 30 days after last E2D administration. In
contrast, the TAM-resistant tumours never expressed higher than
initial values after the finish of therapy. These results indicate
difference in the dynamics of OR expression regulation following
cessation of hormonal treatments between TAM-sensitive and
-resistant breast carcinomas. Both the TAM-sensitive and the
-resistant line expressed equally low levels of the ORb in an
immunohistochemical assay (data not shown).
The PR protein was expressed at 9 ± 8 or 15 ± 16 fmol mg–1
protein (mean ± standard deviation from 5–8 samples each) in the
TAM-sensitive or -resistant line, respectively. A treatment of in
vivo tumours with E2D for several weeks enhanced expression
significantly to 287 ± 104 or 419 ± 358 fmol mg–1, a treatment with
TAM to 84 ± 2 or 77 ± 26 fmol mg–1. This induction of PR expres-
sion suggests a comparable functioning of transcription machinery
independent of a response of the tumours to (anti-) hormonal treat-
ment.
Sequence comparison of the hormone-binding domain
of TAM-sensitive and -resistant mammary carcinoma
3366
In order to evaluate whether the change in sensitivity of TAM
could be attributed to a mutated HBD of the OR, we undertook a
comparative sequence analysis of this region in both the parental
tumour line 3366 and the TAM-resistant subline. The nucleotide
sequence determination was performed by cycle sequencing of
an RT-PCR-amplified 634 bp-fragment encompassing the pos.
1390–2026 (GenBank No X03635) (Green et al, 1986) in the
hormone-binding region of OR-mRNA. The analysed sequences
of both tumour lines – the TAM-sensitive and the -resistant one –
were shown to be absolutely identical. No mutations could be
detected, indicating that no sequence change in the HBD is respon-
sible for the established TAM-resistance of the mammary carci-
noma line 3366. Furthermore, no amino acid replacement in helix
12 (Brzozowski et al, 1997; Maalouf et al, 1998) and the transcrip-
tional activation region 2 (TAF-2) described by others (Montano et
al, 1995) could be found that might lead to agonistic activities
of TAM. The determined sequences differ only in position 1559
(GenBank No X03635) from other published human
OR sequences (GenBank No X03635, M12674, I08538), which
leads to an amino acid substitution from valin to glycine in the
deduced protein sequence. Furthermore, in both tumour lines a
coexpression of an exon 7 splice variant of OR-mRNA could be
detected which was also identified by sequencing. The sequence
data of the HBD of mammary carcinoma line 3366 are available
from EMBL Nucleotide Sequence Database (EBI, Hinxton,
Cambridge, UK) under accession number Z75126.
Expression of oestrogen receptor regulated genes
Gene expression of the two oestrogen regulated genes pS2 and
cathepsin D have been normalized to the ribosomal protein 36B4,
and in Figure 5 the mRNA levels are presented relative to the level
of the respective gene in MCF-7 cells. The pS2 expression is
extremely low in the 3366 tumour, about 33- to 45-fold lower in
control 3366 tumours than in MCF-7 cells (Figure 5A). 3366
tumours from animals treated with oestradiol have a pS2 expression
level as in tumours from animals without treatment. Treatment with
tamoxifen resulted in a decreased expression level of pS2 to about
40% of the level in tumours from untreated animals. The total
group of tamoxifen resistant 3366/TAM tumours have a signifi-
cantly higher pS2 expression level than the total group of 3366
tumours (P < 0.002, Mann Whitney U-test, two-tailed). Treatment
Tamoxifen-resistant breast carcinoma xenograft 1847
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Figure 2 Growth of breast carcinoma 3366 in nude mice (six per group)
during treatment with saline, oestradiol valeriate (E2D, 0.5 mg kg–1 once a
week i.m.), TAM (50 mg kg–1 twice a week i.m.) or ICI 182 780 (25 mg kg–1
twice a week i.m.). Treatment was initiated 1 week after tumour
transplantation (fragment of 2–3 mm diameter, s.c.) and continued until the
end of the experiment
Figure 3 Growth of breast carcinoma 3366/TAM in nude mice (six per
group). For treatment schedules and doses see Figure 2
Figure 4 Regulation of OR expression after cessation of oestradiol
treatment (0.5 mg kg–1 17b-oestradiol valeriate once a week i.m. for
6 weeks). Each value represents the mean ± standard deviation from
5–8 tumours each
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nwith oestradiol or tamoxifen had no significant effect on pS2
expression in 3366/TAM tumours. The cathepsin D expression
level in control 3366 tumours was in the same order of magnitude
as in MCF-7 cells (Figure 5B). 3366 tumours from both oestradiol
and tamoxifen treated animals had higher cathepsin D levels than in
tumours from animals without treatment. Cathepsin D expression
levels in control 3366/TAM tumours were also close to the level in
MCF-7 cells. However, in these tumours, both oestradiol and
tamoxifen reduced the level of cathepsin D expression.
DISCUSSION
Endocrine therapy of breast carcinoma is an established proce-
dure, especially for hormone receptor-positive cancers.
Unfortunately, about one third of the receptor positive patients
originally fail to respond to, for example, the anti-oestrogen
tamoxifen, and another large majority of tumours eventually
develop acquired resistance. Though several hypotheses exist on
the mechanism of anti-oestrogen resistance, the ultimate reasons
still remain unclear (reviews Osborne and Fuqua, 1994; Tonetti
and Jordan, 1995; Lykkesfeldt, 1996).
Investigations concerning the response of cancer cells to anti-
oestrogens mainly utilize molecular approaches or cell lines with
in vitro selection for anti-oestrogen independence (review
Lykkesfeldt, 1997). Only few literature reports refer to in vivo
studies. Osborne et al (1987) and Gottardis and Jordan (1988)
observed an inhibited tumour growth of the MCF-7 line in nude
mice upon oestradiol withdrawal with or without tamoxifen. After
3–4 months of endocrine therapy, tumours started to regrow in a
hormone independent way, though receptor analyses showed
maintained OR- and PR-levels. Later on it was shown in the same
model (Wolf and Jordan, 1994) that an inverse relation between
OR and epidermal growth factor receptor levels existed and that
the E2-induced PR expression was almost completely abolished.
Another group (Thompson et al, 1993) reported on an oestrogen-
independent variant of the MCF-7 line forming locally invasive
structures after transplantation into the mammary fat pad. This
feature was accompanied by elevated levels of the oestrogen-
inducible cathepsin D.
These relatively few literature reports on in vivo models of
hormonal resistance exclusively utilized the MCF-7 model.
Considering the few available OR-positive breast cancer cell lines
(Clarke, 1996) we developed an in vivo model in a relatively clin-
ically related manner. Starting from the very TAM-sensitive, OR-
positive mammary carcinoma 3366, derived from a ductal
invasive carcinoma of a menopausal patient (Naundorf et al,
1992), we developed a TAM-resistant subline by subsequent treat-
ment of tumour-bearing nude mice during passaging with
increasing doses of TAM. After about 3 years the resistance
phenotype was obvious, resulting in a complete lack of remissions
to TAM as was seen in the parental line. As both lines failed to
grow in vitro, further comparative characterization was exclu-
sively performed with the in vivo growing xenografts.
Oestrogen receptor expression
Both lines have to be considered as OR-positive, both concerning
the a- and the b-subtype of the protein. This observation coincides
with literature reports on TAM-resistant sublines of MCF-7
(Gottardis and Jordan, 1988; Osborne et al, 1987; Lykkesfeldt et
al, 1994; Madsen et al, 1997) also maintaining their ORa-posi-
tivity despite anti-oestrogen resistance. Also, it was clinically
reported that in 69% of TAM-resistant tumours the initial OR-level
was maintained (Johnston et al, 1995).
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Figure 5 Phosphorimager scan data showing the levels of pS2 (A) and cathepsin D mRNAs (B) in 3366 and 3366/TAM tumours relative to the level in MCF-7
cells. Animals received either no hormone treatment, treatment with oestradiol or treatment with tamoxifen. Poly (A)+RNA was prepared from homogenized
tumour tissue or MCF-7 cell pellets. The RNA was run on an agarose gel, blotted onto a nylon membrane and the amount of transcripts of pS2, cathepsin D and
36B4 were determined by hybridization with randomly labelled probes. The 36B4 mRNA was used as an internal control and the Phosphorimager scan values
were normalized to the amount of this transcript before expressed relative to the level in MCF-7 cells.Oestrogen receptor regulation
Despite the relatively similar absolute values of OR in the TAM-
sensitive and -resistant sublines, a distinct difference in the
dynamics of expression levels after several weeks’ cessation of
hormone treatment became evident. While in the parental 3366
tumour a transient downregulation (after 1 day) was followed by a
long-standing upregulation (up to 30 days), such an enhancement
was absent in the 3366/TAM subline. This observation can also be
interpreted as a ‘normalizing’ reaction following the probable
downregulation of OR during an oestradiol treatment occurring in
the sensitive, but not the resistant, line.
On the other hand, it has to be kept in mind that in the standard
Abbott EIA a low salt extraction is used for cytosol preparation.
This means that hormone-bound receptors are not released from
the chromatin and only the free receptors are determined. If this is
the case, it is conceivable that a withdrawal of oestradiol treatment
will, upon unchanged OR regulation, also give rise to an increase
in free OR content as no hormone is available for binding to the
ORs. However, this hypothesis delivers no explanation for the
difference in regulation kinetics between the sensitive and the
resistant line.
So far, OR regulation studies have been reported after short-
term (24–48 h) incubation of receptor-positive cell lines with
oestrogen or different anti-oestrogens (Pink et al, 1996; Martin et
al, 1994; Jensen et al, 1999). These results can hardly be compared
with our long-term in vivo effects, but they strengthen the fact that
the OR expression, both on the mRNA and on the protein level, is
strongly dependent on exogenous and endogenous factors and very
dynamically regulated.
Also in a clinical study with breast tumour biopsies (Noguchi et
al, 1993) an upregulation of OR and PR levels following an 8 day
TAM treatment was demonstrated, but not correlated with the
TAM response. Another clinical study evaluating breast cancer OR
and PR levels in 2933 cases (Montella et al, 1996) revealed that
OR positivity was more prevalent in tumours with lobular
histology. This coincides with our observation that, following an
oestradiol treatment of 3366 xenografts, with the proved increase
in OR level a distinct change of histology to a marked lobular
structure was induced. This apparent increase in differentiation
was accompanied by a higher growth rate of the tumours and is
probably a prerequisite for a TAM-response, as the lack of differ-
entiation induction in the resistant line suggests.
Oestrogen receptor structure
The comparative sequence analysis of the hormone binding
domain of the OR isolated from 3366 or 3366/TAM xenografts
revealed them to be absolutely identical. Both lines expressed both
the wild-type fragment and the splice variant 7 in similar quanti-
ties. Though a large amount of molecular studies using artificial
expression systems with a broad variety of OR mutants and vari-
ants have been documented, Tonetti and Jordan (1997) concluded
in a review that at present, ‘no compelling evidence suggests that
mutation of the OR is the molecular mechanism producing TAM-
stimulated growth in human breast cancer’.
This opinion and our results agree with literature reports
(Karnik et al, 1994) documenting mutations of the OR in only two
of 20 TAM-resistant clinical cancers. In addition, Madsen et al
(1997) denied a relation of OR mRNA splice variants to anti-
oestrogen resistance of MCF-7 sublines.
Oestrogen receptor dependent gene and protein
expression
The pS2 mRNA was discovered as the most abundant oestrogen-
regulated mRNA in the human breast cancer cell line MCF-7
(Masiakowski et al, 1982). In human breast tumours, pS2 expres-
sion is correlated to OR expression and is a marker of oestrogen-
dependent breast cancer (Rio et al, 1987; Foekens et al, 1994).
The human 3366 tumour expresses pS2 mRNA, although at a
very low level compared to MCF-7 cells. Treatment with oestra-
diol has no stimulatory effect on pS2 expression. This may be
due to presence of low oestrogen levels in untreated animals.
Tamoxifen acts as an oestrogen antagonist with respect to pS2
expression in 3366 tumour cells, and this is in concert with the
antagonistic activity of tamoxifen on pS2 expression in MCF-7
cells (Westley et al, 1984; Lykkesfeldt et al, 1994). Cathepsin D
was the first oestrogen-regulated protein secreted from MCF-7
cells to be described (Westley and Rochefort, 1980). In the 3366
tumour the cathepsin D mRNA expression level is comparable
to the level in MCF-7 cells. A small induction of cathepsin D
mRNA expression is observed in tumours from animals treated
with oestradiol or with tamoxifen. This agonistic effect of both
oestradiol and tamoxifen has also been seen in MCF-7 cells
(Lykkesfeldt et al, 1994). Thus, in the OR-positive 3366 estab-
lished from a human breast tumour sample, pS2 and cathepsin D
regulation is similar to MCF-7 cells.
The tamoxifen-resistant 3366/TAM tumours appear to have an
increased pS2 expression level compared to the 3366 tumours.
Increased basal pS2 expression has also been observed in the
tamoxifen resistant MCF-7/TAMR-1 cells (Lykkesfeldt et al,
1994) and in ICI 182 780 resistant MCF-7 cell lines (Larsen et al,
1997). Tamoxifen does not downregulate pS2 expression in
3366/TAM tumours as in 3366 tumours, indicating loss of effect
of tamoxifen on regulation of this gene. With respect to regula-
tion of cathepsin D expression, both oestradiol and tamoxifen act
as antagonists in the tamoxifen-resistant tumours 3366/TAM.
These data indicate a change in the response to oestrogen and
anti-oestrogen in the tamoxifen-resistant tumours and studies
elucidating the underlying causes for these changed responses
may provide important new information on OR-mediated gene
expression.
In summary, the newly developed TAM-resistant subline of an
OR-positive breast carcinoma represents a clinically relevant
model for studying both mechanisms of anti-oestrogen resistance
and for testing approaches to prevent or to overcome this pheno-
type. We show that neither absolute levels of OR expression nor
mutations in the HBD are associated with TAM-resistance, but
that the ability to regulate OR and oestrogen-responsive gene
expression is apparently linked with the potential to respond to
an anti-oestrogen treatment. Further studies to elucidate other
probable mechanisms of TAM-resistance, like involvement of
oestrogen receptor- or transcription-associated cofactors, are
underway utilizing the in vivo model described here.
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